Q3 2020 Sales Performance
Strong momentum on 2DRs
Strong execution across portfolio
US DTG NBRx share outpacing DTG TRX share
gsk
-
Leading share of voice in US and Europe
29%
28%
-
Strong execution with 2DRs, driving uptake (NBRX:
>8%)
27%
26%
25%
Dovato US label expansion to include TANGO data;
driving increased share in switch market
24%
23%
- Additional supportive data from 96-week TANGO
switch and 144-week GEMINI studies
Positive start for Rukobia; US insurance coverage
70%
CAB PrEP filing with FDA on track for H1 2021 -
approval anticipated Q1 2022
22%
21%
20%
www
سیر
Oct-18
Nov-18
Dec-18
Jan-19
Feb-19
Mar-19
Market at point of inflection as 2DRs
gain traction
Apr-19
May-19
Jun-19
Jul-19
Aug-19
Sep-19
Oct-19
Nov-19
Dec-19
Jan-20
DTG NBRX share
Feb-20
Mar-20
Apr-20
May-20
Jun-20
Jul-20
Aug-20
Sep-20
DTG TRX share
29
29View entire presentation